ArticleJournal of the American Heart Association2026
Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn symptomatic patients with treatment-refractory obstructive hypertrophic cardiomyopathy, septal reduction therapy (SRT) is recommended to relieve obstruction. This study examined the challenges associated with SRT access in the United States.
methodsCross-sectional study of commercially insured individuals or Medicare Advantage with Part D members captured in the Optum Research Database from May 2012 to April 2022. Patients with obstructive hypertrophic cardiomyopathy who underwent SRT were identified based on diagnosis/procedure codes. Treatment center procedural volume was defined based on tertiles. SRT access was assessed by the distance patients traveled to care and the proportion of patients treated at hypertrophic cardiomyopathy centers of excellence (COE) by region. Cohorts of patients with coronary artery disease who underwent percutaneous coronary intervention or coronary artery bypass grafting were compared with the SRT cohort.
resultsOverall, 1864 patients who underwent SRT, 235 652 with percutaneous coronary intervention, and 69 236 with coronary artery bypass grafting were included. In the SRT cohort, 368 patients (19.7%) underwent procedures at COE. A greater proportion of patients who traveled long distances for care (≥50 miles) underwent SRT at COE (35.7%) or high-volume facilities (43.8%) than those who traveled short distances (0-<10 miles; 13.3% and 28.1%, respectively). Mean distance to care was longer for the SRT cohort than the percutaneous coronary intervention/coronary artery bypass grafting cohorts. Among US regions, the proportion of patients who underwent SRT at standard centers versus COE was highest in the South (87.5% versus 12.5%).
conclusionsPatients traveled long distances for SRT at COE/high-volume centers. Most patients received SRT at standard centers rather than at COE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.